Articles with public access mandates - Paul M Ridker, MD, MPHLearn more
Not available anywhere: 43
Review
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo …
PM Ridker, JG MacFadyen, T Thuren, BM Everett, P Libby, RJ Glynn, ...
The Lancet 390 (10105), 1833-1842, 2017
Mandates: US National Institutes of Health
Review
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
PM Ridker, M Devalaraja, FMM Baeres, MDM Engelmann, GK Hovingh, ...
The Lancet 397 (10289), 2060-2069, 2021
Mandates: US National Institutes of Health, American Heart Association
Review
Targeting cardiovascular inflammation: next steps in clinical translation
PR Lawler, DL Bhatt, LC Godoy, TF Lüscher, RO Bonow, S Verma, ...
European heart journal 42 (1), 113-131, 2021
Mandates: US National Institutes of Health, Canadian Institutes of Health Research
Review
AJC editor's consensus: psoriasis and coronary artery disease
VE Friedewald, JC Cather, JM Gelfand, KB Gordon, GH Gibbons, ...
American Journal of Cardiology 102 (12), 1631-1643, 2008
Mandates: US National Institutes of Health
Review
Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an …
PM Ridker, J MacFadyen, P Libby, RJ Glynn
The American journal of cardiology 106 (2), 204-209, 2010
Mandates: US National Institutes of Health
Review
Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials
PM Ridker, DL Bhatt, AD Pradhan, RJ Glynn, JG MacFadyen, SE Nissen
The Lancet 401 (10384), 1293-1301, 2023
Mandates: US National Institutes of Health, Patient-Centered Outcomes Research Institute
Review
Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy
JS Danik, DI Chasman, JG MacFadyen, F Nyberg, BJ Barratt, PM Ridker
American heart journal 165 (6), 1008-1014, 2013
Mandates: US National Institutes of Health, Doris Duke Charitable Foundation
Review
Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: exploratory analysis of a randomized controlled trial
DH Solomon, RJ Glynn, JG MacFadyen, P Libby, T Thuren, BM Everett, ...
Annals of internal medicine 169 (8), 535-542, 2018
Mandates: US National Institutes of Health
Review
Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (< 30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER)
BM Everett, S Mora, RJ Glynn, J MacFadyen, PM Ridker
The American journal of cardiology 114 (11), 1682-1689, 2014
Mandates: US National Institutes of Health
Review
Targeting innate immunity-driven inflammation in CKD and cardiovascular disease
T Speer, S Dimmeler, SJ Schunk, D Fliser, PM Ridker
Nature Reviews Nephrology 18 (12), 762-778, 2022
Mandates: German Research Foundation
Review
Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases.
Lp-PLA2 Studies Collaboration
European Journal of Preventive Cardiology 14 (1), 3-11, 2007
Mandates: British Heart Foundation
Review
Association of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with the risk of thromboembolism and mortality in patients with cancer
E Grilz, F Posch, O Königsbrügge, I Schwarzinger, IM Lang, C Marosi, ...
Thrombosis and haemostasis 118 (11), 1875-1884, 2018
Mandates: Austrian Science Fund
Review
Measures to assess the prognostic ability of the stratified Cox proportional hazards model
Fibrinogen Studies Collaboration
Statistics in Medicine 28 (3), 389-411, 2009
Mandates: British Heart Foundation
Review
Complete blood count risk score and its components, including RDW, are associated with mortality in the JUPITER trial
BD Horne, JL Anderson, JB Muhlestein, PM Ridker, NP Paynter
European journal of preventive cardiology 22 (4), 519-526, 2015
Mandates: US National Institutes of Health
Review
Purinergic receptor P2Y, G-protein coupled, 12 gene variants and risk of incident ischemic stroke, myocardial infarction, and venous thromboembolism
RYL Zee, SE Michaud, KA Diehl, DI Chasman, J Emmerich, P Gaussem, ...
Atherosclerosis 197 (2), 694-699, 2008
Mandates: US National Institutes of Health
Review
C-reactive protein gene variation and type 2 diabetes mellitus: A case–control study
RYL Zee, S Germer, A Thomas, A Raji, B Rhees, PM Ridker, ...
Atherosclerosis 197 (2), 931-936, 2008
Mandates: US National Institutes of Health
Review
Venous thromboembolism in patients with symptomatic atherosclerosis
G Piazza, SZ Goldhaber, DM Lessard, RJ Goldberg, C Emery, ...
Thrombosis and haemostasis 106 (12), 1095-1102, 2011
Mandates: US National Institutes of Health
Review
Prospective association of vascular endothelial growth factor-A (VEGF-A) with coronary heart disease mortality in southeastern New England
CB Eaton, R Gramling, DR Parker, MB Roberts, B Lu, PM Ridker
Atherosclerosis 200 (1), 221-227, 2008
Mandates: US National Institutes of Health
Review
The JUPITER Trial: responding to the critics
PM Ridker, RJ Glynn
American Journal of Cardiology 106 (9), 1351-1356, 2010
Mandates: US National Institutes of Health
Review
Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy
PM Ridker, KR Tuttle, V Perkovic, P Libby, JG MacFadyen
European heart journal 43 (46), 4832-4844, 2022
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program